Efficacy and Tolerability of Fluvastatin and Simvastatin in Hypercholesterolaemic Patients

被引：0

作者：

J. A. Tobert

A. V. Katdare

K.-L. Schulte

S. Beil

机构：

[1] Merck Research Laboratories,Departments of Clinical Research and Pharmaceutical Research and Development

[2] Merck Research Laboratories,Departments of Clinical Research and Pharmaceutical Research and Development

[3] Ev. Krankenhaus Königin Elizabeth Herzberge,undefined

[4] Städt. Krankenhause,undefined

来源：

Clinical Drug Investigation | 1997年 / 13卷 / 1期

关键词：

D O I：

10.2165/00044011-199713010-00007

中图分类号：

学科分类号：

摘要：

引用

页码：56 / 57

页数：1

共 50 条

[21] A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: A randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease
van Dam, MJ
Penn, HJAM
den Hartog, FR
Kragten, HA
Trip, MD
Buirma, RJA
Kastelein, JJP
CLINICAL THERAPEUTICS, 2001, 23 (03) : 467 - 478
[22] SAFETY, TOLERABILITY, AND EFFICACY OF SIMVASTATIN AND FENOFIBRATE - A MULTICENTER STUDY
ZIEGLER, O
DROUIN, P
CARDIOLOGY, 1990, 77 : 50 - 57
[23] Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia
Recto, CS
Acosta, S
Dobs, A
CLINICAL CARDIOLOGY, 2000, 23 (09) : 682 - 688
[24] COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN - REPLY
SWEANY, AE
SHAPIRO, DR
TATE, AC
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (09): : 723 - 724
[25] COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN FOR HYPERCHOLESTEROLEMIA
DAUBRESSE, JC
DEBACKER, G
DUCOBU, J
HARVENGT, C
DEGENNES, JL
DOUSTEBLAZY, P
FARNIER, M
ANDERS, G
DAMMANN, HG
NEUMANN, E
SCHWARZE, B
SEIFART, C
KASTELEIN, J
STALENHOEF, A
KEIDAR, S
CAPURSO, A
DECESARIS, R
DESCOVICH, G
FELLIN, R
FERUGLIO, F
MALINI, P
TRIMARCO, B
SCOTT, R
MARAIS, A
KELLER, U
MOCCETTI, T
BLOOMFIELD, P
CRAMB, R
HUGHES, E
SEED, M
WRAY, R
STEIN, E
FRUCHART, J
SWEANY, A
SHAPIRO, D
TATE, A
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (16): : 1408 - 1414
[26] EFFICACY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (MULTICOUNTRY COMPARATIVE-STUDY)
LEFEBVRE, P
SCHEEN, A
MATERNE, P
POPEYE, R
QUOIDBACH, A
BERCOVICI, JP
CHADENAS, D
DEVULDER, B
DOUSTEBLAZY, P
LOUVET, JP
FARNIER, M
GANCEL, A
HAUTECOUVERTURE, M
PINGET, M
ROGER, P
VAGUE, P
FEELY, J
FENNELL, W
TOMKIN, G
MALINI, PL
STROCCHI, E
DEDIVITIIS, O
DISOMMA, S
ROSIELLO, G
TRIMARCO, B
LANSBERG, PJ
KASTELEIN, JJP
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (15): : 1281 - 1286
[27] LONG-TERM EFFICACY AND TOLERABILITY OF SIMVASTATIN IN A LARGE COHORT OF ELDERLY HYPERCHOLESTEROLEMIC PATIENTS
LANSBERG, PJ
MITCHEL, YB
SHAPIRO, D
KASTELEIN, JJP
ALTMAN, R
JERUMS, G
BOLZANO, K
GIANNINI, S
DAVIGNON, J
DEWAILLY, P
DARIOLI, R
MANCINI, M
SCOTT, R
HAYDEN, MR
ATHEROSCLEROSIS, 1995, 116 (02) : 153 - 162
[28] Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia
Tvorogova, MG
Susekov, AV
Semenova, OA
Kukharchuk, VV
Titov, VN
TERAPEVTICHESKII ARKHIV, 1998, 70 (12) : 8 - 13
[29] Simvastatin decreases monocyte chemoattractant protein-1 in hypercholesterolaemic patients
Rallidis, L.
Hamodraka, E.
Moustogiannis, G.
Salichou, C.
Gika, H.
Velissaridou, A.
Kremastinos, D.
ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 574 - 574
[30] Addressing a Treatment GapRationale for Increasing the Starting Dose of Simvastatin in Hypercholesterolaemic Patients
Jonathan Isaacsohn
Jonathan A. Tobert
Amy O. Johnson-Levonas
Pamela Landsman
Clinical Drug Investigation, 2002, 22 : 291 - 301

← 1 2 3 4 5 →